Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Cleveland BioLabs Inc | CBLI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 0.659475 | 0.00 | 0.00 | 0.00 | 0.659475 | 07:29:35 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 0.01 | 1.01 | 1.00 | 99.01% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Cleveland BioLabs Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 7.45M | 11.30M | $ -3.61M | -0.33 | - | 7.64M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Cleveland BioLabs News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CBLI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.68 | 0.69 | 0.62 | 0.6451335 | 4,631 | -0.02053 | -3.02% |
| 1 Month | 0.9765 | 0.9765 | 0.62 | 0.7868935 | 20,169 | -0.31703 | -32.47% |
| 3 Months | 1.4275 | 1.518 | 0.62 | 0.9851827 | 15,356 | -0.76803 | -53.8% |
| 6 Months | 1.63 | 1.70 | 0.62 | 1.13 | 9,640 | -0.97053 | -59.54% |
| 1 Year | 1.71 | 2.17 | 0.62 | 1.41 | 13,519 | -1.05 | -61.43% |
| 3 Years | 1.5566 | 5.55 | 0.62 | 4.09 | 138,519 | -0.89713 | -57.63% |
| 5 Years | 0.3801 | 7.24 | 0.19 | 3.79 | 147,171 | 0.27938 | 73.5% |
Cleveland BioLabs Description
| Cleveland BioLabs Inc is a biopharmaceutical company. The company is developing novel approaches to activate the immune system and address serious medical needs. Its proprietary platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its lead product candidate is entolimod, an immuno-stimulatory agent, which is developed as a radiation countermeasure and an immunotherapy for oncology and other indications. Entolimod is a Toll-like receptor 5 (TLR5) agonist, which is developed as a radiation countermeasure for prevention of death from Acute Radiation Syndrome (ARS), and as an oncology drug. |
